SEC Form 4 · accession 0001553878-18-000026
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry E Greene
Officer — President
Period of report
Mar 14, 2018
Accepted (ET)
Mar 16, 2018 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 14, 2018 | S | 2,884 | $140.43 | D | 97,544 | D | |
| Common StockF3 | Mar 14, 2018 | S | 7,250 | $141.74 | D | 90,294 | D | |
| Common StockF4 | Mar 14, 2018 | S | 9,217 | $142.68 | D | 81,077 | D | |
| Common StockF5 | Mar 14, 2018 | S | 8,644 | $143.58 | D | 72,433 | D | |
| Common StockF6 | Mar 14, 2018 | S | 9,165 | $144.67 | D | 63,268 | D | |
| Common StockF7 | Mar 14, 2018 | S | 1,300 | $145.41 | D | 61,968 | D | |
| Common StockF8 | holding | — | — | — | 2,810 | I | by Managed Account |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018.
- F2Sale prices ranged from $140.00 to $140.95
- F3Sale prices ranged from $141.12 to $142.10
- F4Sale prices ranged from $142.12 to $143.11
- F5Sale prices ranged from $143.12 to $144.11
- F6Sale prices ranged from $144.14 to $145.13
- F7Sale prices ranged from $145.16 to $145.79
- F8The reporting person owns 2,827 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.